Avita Medical Ltd (RCEL) Stock Forecast & Price Target
Avita Medical Ltd · NASDAQ
$4.76+0.15 (+3.25%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Avita Medical Ltd, 3 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $6.00 to $10.00, a moderate spread. The average target of $8.00 sits 68% above the current $4.76. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.35 next quarter toward $-0.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy375%
Hold125%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Avita Medical Ltd.
As of Jul, 3 of 4 firms rate RCEL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RCEL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.35
Range $-0.44 – $-0.27 · 4 analysts · -51% YoY
Next period, 4 analysts expect Avita Medical Ltd to earn $-0.35 a share (range $-0.44 – $-0.27), versus $-0.71 a year earlier. Full-year consensus is $-1.45, growing to $-0.85 the year after.
REVENUE · NEXT QUARTER
$29.5M
Range $27.9M – $31.4M · 4 analysts · +12% YoY
Revenue is expected to reach $29.5M (range $27.9M – $31.4M), +11.8% year-over-year. Full-year consensus is $118.2M, rising to $151.8M next year.
Top analysts covering Avita Medical Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RCEL.
#1
Ross Osborn
Cantor Fitzgerald · Rank #139
Buy
$11.00+131.1% to target
Overall win rate
34%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #327
Buy
$6.00+26.1% to target
Overall win rate
26%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$10.00+110.1% to target
Overall win rate
22%
+ Follow
RCEL stock forecast FAQ
What is RCEL's average 12-month price target?+
The 2 analysts with a live target average $8.00 for Avita Medical Ltd over the next 12 months, ranging from a $10.00 high to a $6.00 low.
Is RCEL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 3 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RCEL?+
The Street-high target is $10.00 (D. Boral Capital), and the Street-low is $6.00 (Lake Street). The average of all 2 active targets is $8.00.
How many Wall Street analysts cover RCEL?+
4 analysts have an active rating on Avita Medical Ltd, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RCEL?+
Among analysts who currently cover RCEL, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #139). Their current call is Buy with a $11.00 target.
What is Avita Medical Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.35 per share (range $-0.44 – $-0.27) across 4 analysts. Full-year EPS is projected at $-1.45, rising to $-0.85 the following year.
How much revenue is Avita Medical Ltd expected to report next quarter?+
Consensus revenue is $29.5M (range $27.9M – $31.4M). Full-year revenue is projected at $118.2M, growing to $151.8M next year.
Have analysts been upgrading or downgrading RCEL lately?+
As of Jul, 3 of 4 firms rate RCEL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RCEL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
